Tel Aviv - Delayed Quote ILA
Enlivex Therapeutics Ltd. (ENLV.TA)
356.70
-10.20
(-2.78%)
At close: 3:49:59 PM GMT+3
Key Executives
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in ILA.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Shai Novik M.B.A. | Executive Chairman | 528k | -- | 1966 |
| Dr. Oren Hershkovitz Ph.D. | Chief Executive Officer | 273.6k | -- | 1977 |
| Prof. Dror Mevorach M.D. | Founder & Scientific Advisor | 180k | -- | 1956 |
| Ms. Shachar Shlosberger CPA | Chief Financial Officer | 126k | -- | 1977 |
| Dr. Veronique Amor-Baroukh | Senior Director of Operations | -- | -- | -- |
| Ms. Sigal Arad | Director of Human Resources | -- | -- | -- |
| Dr. Einat Galamidi M.D. | Chief Medical Officer | -- | -- | 1974 |
Enlivex Therapeutics Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Corporate Governance
Enlivex Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
SCNI Scinai Immunotherapeutics Ltd.
2.9100
+5.43%
BCLI Brainstorm Cell Therapeutics Inc.
1.3200
+13.79%
CGEN Compugen Ltd.
1.3900
+1.46%
NRXP NRx Pharmaceuticals, Inc.
2.4500
+2.08%
URGN UroGen Pharma Ltd.
7.31
-25.79%
IVVD Invivyd, Inc.
0.7767
+10.33%
KLTO Klotho Neurosciences, Inc.
0.2246
+14.01%
CABA Cabaletta Bio, Inc.
2.0300
+12.15%
CNSP CNS Pharmaceuticals, Inc.
1.2800
+1.59%
HCWB HCW Biologics Inc.
8.95
+9.15%